Skip to main content
. 2017 May 29;8(29):48110–48125. doi: 10.18632/oncotarget.18262

Table 1. Relations between the level of YB-1 or MACC1 expression and clinicopathologic characteristics in lung adenocarcinoma.

Characteristics YB-1 P-value MACC1 P-value
High(%) Low High(%) Low
Over all 80(44.7) 99 92(51.4) 87
Sex 0.761 0.489
 Male 41(43.6) 53 46 (48.9) 48
 Female 39(45.9) 46 46(54.1) 39
Age 0.791 0.831
 ≤69y 42(45.7) 50 48(52.2) 44
 >69y 38(43.7) 49 44(50.6) 43
TNM stage <0.001 <0.001
 I 48(34.3) 92 60(42.9) 80
 II 13(76.5) 4 12(70.6) 5
 IIIA 16 (84.2) 3 17(89.5) 2
 IIIB/IV 3(100) 0 3(100) 0
T states <0.001 0.033
 T1 40(33.6) 79 54(45.4) 65
 T2 31(62.0) 19 29(58.0) 21
 T3 6 (85.7) 1 6(85.7) 1
 T4 3(100) 0 3(100) 0
N states <0.001 <0.001
 N0 51(35.4) 93 63(43.8) 81
 N1 13(81.2) 3 12(75.0) 4
 N2 16(84.2) 3 17(89.5) 2
Differentiation 0.038 0.416
 Well 35(36.1) 62 47(48.5) 50
 Moderate 36(53.7) 31 35 (52.2) 32
 Poor 9 (60.0) 6 10(66.7) 5